Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oeparol is a line of dietary supplements and dermocosmetic products developed by Adamed Pharma. The primary active ingredient is cold-pressed evening primrose oil (*Oenothera biennis*), which is a rich source of omega-6 polyunsaturated fatty acids, specifically gamma-linolenic acid (GLA) and linoleic acid (LA). These fatty acids are essential for maintaining the skin's lipid barrier, improving hydration, elasticity, and firmness. The product range includes oral capsules for systemic support and topical formulations like creams and lip balms for direct skin nourishment. Specific variants like Oeparol Femina combine evening primrose oil with flaxseed oil to support women's health, while Oeparol Stimulance incorporates Pro-Retinol for anti-aging benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on evening primrose oil (Adamed Pharma).